Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,079,824
  • Shares Outstanding, K 2,537,829
  • Annual Sales, $ 50,266 M
  • Annual Income, $ 5,844 M
  • EBIT $ 10,835 M
  • EBITDA $ 16,021 M
  • 60-Month Beta 0.58
  • Price/Sales 2.59
  • Price/Cash Flow 7.43
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 20.89% ( -2.89%)
  • Historical Volatility 27.43%
  • IV Percentile 23%
  • IV Rank 16.99%
  • IV High 39.81% on 04/24/24
  • IV Low 17.02% on 03/11/24
  • Put/Call Vol Ratio 0.39
  • Today's Volume 1,016
  • Volume Avg (30-Day) 1,044
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 43,703
  • Open Int (30-Day) 41,204

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.77
  • Number of Estimates 3
  • High Estimate 0.95
  • Low Estimate 0.66
  • Prior Year 0.89
  • Growth Rate Est. (year over year) -13.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.80 +4.17%
on 12/16/24
49.73 -4.06%
on 12/17/24
-0.07 (-0.15%)
since 11/20/24
3-Month
45.80 +4.17%
on 12/16/24
57.97 -17.70%
on 10/01/24
-9.92 (-17.21%)
since 09/20/24
52-Week
45.22 +5.51%
on 04/18/24
58.97 -19.09%
on 09/04/24
-0.50 (-1.04%)
since 12/20/23

Most Recent Stories

More News
Why Cytokinetics Stock Was a Nearly 5% Winner Today

California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in...

CYTK : 48.87 (+4.56%)
SNY : 47.71 (+0.44%)
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

This week, Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary...

MRK : 98.05 (-1.48%)
TEVA : 22.09 (+3.66%)
ABBV : 175.58 (+2.37%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance

Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants...

AZN : 65.35 (+1.41%)
MRK : 98.05 (-1.48%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment...

JNJ : 144.47 (+0.62%)
TEVA : 22.09 (+3.66%)
ABBV : 175.58 (+2.37%)
SNY : 47.71 (+0.44%)
Teva Stock Surges To 6-Year High On Inflammatory Bowel Disease Drug Trial Data: Retail Chatter Erupts

Investors are now eyeing duvakitug’s potential to become a significant revenue driver for both companies, especially as there is currently no cure for IBD.

TEVA : 22.09 (+3.66%)
SNY : 47.71 (+0.44%)
Regeneron Down 15.5% Year to Date: How to Play the Stock?

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during...

BAYRY : 4.9100 (-0.41%)
REGN : 701.85 (-0.90%)
RHHBY : 34.5000 (+0.76%)
SNY : 47.71 (+0.44%)
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?

GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below....

HLN : 9.69 (-0.10%)
MRNA : 39.39 (-0.43%)
GSK : 33.60 (+0.51%)
SNY : 47.71 (+0.44%)
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors

Many companies that performed well in the early pandemic years have since fallen off the radar or at least have seen their shares drop substantially during the past three years. Telemedicine Teladoc Health...

TDOC : 9.44 (+5.24%)
NVAX : 8.70 (+0.23%)
SNY : 47.71 (+0.44%)
Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Despite Pfizer's underperformance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.

XLV : 138.00 (+1.26%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)
NVIDIA Invested in These 2 AI Stocks, Should You?

Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.

SERV : 14.61 (+9.36%)
NVDA : 134.70 (+3.08%)
OUST : 11.98 (+14.97%)
MGA : 42.22 (+2.28%)
SHAK : 128.87 (-0.59%)
RXRX : 6.03 (-0.99%)
EXAI : 4.84 (+3.20%)
RHHBY : 34.5000 (+0.76%)
CMG : 61.87 (+0.21%)
UBER : 60.73 (+0.86%)
SNY : 47.71 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 49.12
2nd Resistance Point 48.51
1st Resistance Point 48.11
Last Price 47.71
1st Support Level 47.10
2nd Support Level 46.49
3rd Support Level 46.09

See More

52-Week High 58.97
Fibonacci 61.8% 53.72
Fibonacci 50% 52.10
Fibonacci 38.2% 50.47
Last Price 47.71
52-Week Low 45.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar